Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043132984> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2043132984 endingPage "591" @default.
- W2043132984 startingPage "591" @default.
- W2043132984 abstract "The efficacy and safety of continuing multiple anti-HER2 therapies in advanced breast cancer (ABC) patients remains unclear. This study investigated eribulin in combination with pertuzumab and trastuzumab for both taxane- and trastuzumab-pretreated HER2-positive ABC patients.In a single-institute, single-arm, open-label, phase II trial, HER2-positive ABC patients who had previously received taxanes and trastuzumab were treated with eribulin in combination with pertuzumab and trastuzumab. The pharmacokinetics of eribulin in this combination were assessed in 6 patients. Tumor assessments were conducted every 6 weeks for the first 6 cycles and every 12 weeks thereafter. The primary endpoint was objective response rate (ORR).A total of 30 patients (median age, 58 years; range, 31–76) were enrolled, with a median number of previous chemotherapy regimens of 3.5 (range: 1–9) in the metastatic setting. Pharmacokinetic parameters of eribulin in this combination were similar to previous reports of eribulin monotherapy. ORR was 34.8% (95% CI: 16.4–57.3, n = 23), and median progression-free survival was 42.6 weeks (95% CI: 20.3–51.9, n = 30). Clinical benefit rate was 60.9% (95% CI: 16.4–57.3). The most common grade 3/4 adverse event was neutropenia in 20 patients (66.7%). A dose reduction of eribulin was required in 27 patients due to adverse events, particularly grade 3 neutropenia.Eribulin in combination with pertuzumab and trastuzumab was well tolerated in heavily pretreated patients. Eribulin may be a viable treatment option when used in combination with pertuzumab and trastuzumab for HER2-positive ABC patients (UMIN Clinical Trial Registry identification number, UMIN000012375)." @default.
- W2043132984 created "2016-06-24" @default.
- W2043132984 creator A5002728271 @default.
- W2043132984 creator A5002860762 @default.
- W2043132984 creator A5018262677 @default.
- W2043132984 creator A5021550191 @default.
- W2043132984 creator A5034364316 @default.
- W2043132984 creator A5042202815 @default.
- W2043132984 creator A5046601855 @default.
- W2043132984 creator A5060947297 @default.
- W2043132984 creator A5070989506 @default.
- W2043132984 creator A5086102127 @default.
- W2043132984 date "2009-09-01" @default.
- W2043132984 modified "2023-10-17" @default.
- W2043132984 title "9403 Eribulin mesylate (E7389) in patients with leiomyosarcoma (LMS) and other (OTH) subtypes of soft tissue sarcoma (STS): a Phase II study from the European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC 62052)" @default.
- W2043132984 doi "https://doi.org/10.1016/s1359-6349(09)71991-3" @default.
- W2043132984 hasPublicationYear "2009" @default.
- W2043132984 type Work @default.
- W2043132984 sameAs 2043132984 @default.
- W2043132984 citedByCount "1" @default.
- W2043132984 countsByYear W20431329842013 @default.
- W2043132984 crossrefType "journal-article" @default.
- W2043132984 hasAuthorship W2043132984A5002728271 @default.
- W2043132984 hasAuthorship W2043132984A5002860762 @default.
- W2043132984 hasAuthorship W2043132984A5018262677 @default.
- W2043132984 hasAuthorship W2043132984A5021550191 @default.
- W2043132984 hasAuthorship W2043132984A5034364316 @default.
- W2043132984 hasAuthorship W2043132984A5042202815 @default.
- W2043132984 hasAuthorship W2043132984A5046601855 @default.
- W2043132984 hasAuthorship W2043132984A5060947297 @default.
- W2043132984 hasAuthorship W2043132984A5070989506 @default.
- W2043132984 hasAuthorship W2043132984A5086102127 @default.
- W2043132984 hasConcept C121608353 @default.
- W2043132984 hasConcept C126322002 @default.
- W2043132984 hasConcept C143998085 @default.
- W2043132984 hasConcept C197934379 @default.
- W2043132984 hasConcept C2775930923 @default.
- W2043132984 hasConcept C2776387010 @default.
- W2043132984 hasConcept C2776694085 @default.
- W2043132984 hasConcept C2777063308 @default.
- W2043132984 hasConcept C2779786085 @default.
- W2043132984 hasConcept C2781164504 @default.
- W2043132984 hasConcept C530470458 @default.
- W2043132984 hasConcept C71924100 @default.
- W2043132984 hasConceptScore W2043132984C121608353 @default.
- W2043132984 hasConceptScore W2043132984C126322002 @default.
- W2043132984 hasConceptScore W2043132984C143998085 @default.
- W2043132984 hasConceptScore W2043132984C197934379 @default.
- W2043132984 hasConceptScore W2043132984C2775930923 @default.
- W2043132984 hasConceptScore W2043132984C2776387010 @default.
- W2043132984 hasConceptScore W2043132984C2776694085 @default.
- W2043132984 hasConceptScore W2043132984C2777063308 @default.
- W2043132984 hasConceptScore W2043132984C2779786085 @default.
- W2043132984 hasConceptScore W2043132984C2781164504 @default.
- W2043132984 hasConceptScore W2043132984C530470458 @default.
- W2043132984 hasConceptScore W2043132984C71924100 @default.
- W2043132984 hasIssue "2" @default.
- W2043132984 hasLocation W20431329841 @default.
- W2043132984 hasOpenAccess W2043132984 @default.
- W2043132984 hasPrimaryLocation W20431329841 @default.
- W2043132984 hasRelatedWork W1838780608 @default.
- W2043132984 hasRelatedWork W2092771806 @default.
- W2043132984 hasRelatedWork W2327550265 @default.
- W2043132984 hasRelatedWork W2407902240 @default.
- W2043132984 hasRelatedWork W2640246504 @default.
- W2043132984 hasRelatedWork W2769791634 @default.
- W2043132984 hasRelatedWork W3023019229 @default.
- W2043132984 hasRelatedWork W4205733538 @default.
- W2043132984 hasRelatedWork W4244633258 @default.
- W2043132984 hasRelatedWork W4250702997 @default.
- W2043132984 hasVolume "7" @default.
- W2043132984 isParatext "false" @default.
- W2043132984 isRetracted "false" @default.
- W2043132984 magId "2043132984" @default.
- W2043132984 workType "article" @default.